Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Total Debt (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Total Debt data on record, last reported at $16.9 million in Q3 2025.

  • For Q3 2025, Total Debt fell 43.61% year-over-year to $16.9 million; the TTM value through Sep 2025 reached $16.9 million, down 43.61%, while the annual FY2024 figure was $22.0 million, 25.51% down from the prior year.
  • Total Debt reached $16.9 million in Q3 2025 per NWBO's latest filing, down from $18.3 million in the prior quarter.
  • Across five years, Total Debt topped out at $358.6 million in Q1 2021 and bottomed at $8.1 million in Q1 2025.
  • Average Total Debt over 5 years is $83.1 million, with a median of $24.6 million recorded in 2022.
  • Peak YoY movement for Total Debt: soared 3127.05% in 2021, then plummeted 93.18% in 2022.
  • A 5-year view of Total Debt shows it stood at $131.9 million in 2021, then tumbled by 34.4% to $86.6 million in 2022, then crashed by 65.92% to $29.5 million in 2023, then decreased by 25.51% to $22.0 million in 2024, then fell by 23.3% to $16.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $16.9 million in Q3 2025, $18.3 million in Q2 2025, and $8.1 million in Q1 2025.